• Je něco špatně v tomto záznamu ?

Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment

D. Krejci, P. Opalka, J. Krejci, M. Zemanova, P. Zemanova, J. Kultan, O. Fischer, J. Skrickova, M. Bratova, M. Cernovska, M. Hrnciarik, H. Coupkova, K. Hurdalkova, M. Barinova, L. Koubkova, D. Dolezal, M. Safanda, M. Pesek, M. Svaton

. 2021 ; 41 (5) : 2597-2603. [pub] -

Jazyk angličtina Země Řecko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc21018654

BACKGROUND/AIM: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens. PATIENTS AND METHODS: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. RESULTS: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. CONCLUSION: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc21018654
003      
CZ-PrNML
005      
20210830100241.0
007      
ta
008      
210728s2021 gr f 000 0|eng||
009      
AR
024    7_
$a 10.21873/anticanres.15039 $2 doi
035    __
$a (PubMed)33952489
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a gr
100    1_
$a Krejci, Daniel $u Department of Pneumology, Third Faculty of Medicine and Bulovka University Hospital, Charles University, Prague, Czech Republic
245    10
$a Comparison of Chemotherapeutic Regimens Frequently Used in Metastatic Non-squamous NSCLC Treatment / $c D. Krejci, P. Opalka, J. Krejci, M. Zemanova, P. Zemanova, J. Kultan, O. Fischer, J. Skrickova, M. Bratova, M. Cernovska, M. Hrnciarik, H. Coupkova, K. Hurdalkova, M. Barinova, L. Koubkova, D. Dolezal, M. Safanda, M. Pesek, M. Svaton
520    9_
$a BACKGROUND/AIM: Platinum-based chemotherapy with pemetrexed or paclitaxel/bevacizumab are regimens used in combination with checkpoint inhibitors in non-squamous non-small cell lung cancer (NSCLC) treatment. We conducted a real-world study to compare the outcomes of these chemotherapeutic regimens. PATIENTS AND METHODS: We investigated 1,534 patients with advanced non-squamous NSCLC treated with platin/pemetrexed (n=1212) or platin/paclitaxel/bevacizumab (n=322) in 9 cancer centres in the Czech Republic. RESULTS: The regimen containing platin/paclitaxel/bevacizumab showed significantly better overall response rate (ORR) compared to the platin/pemetrexed [40.8% vs. 32.7% (p=0.008)] in the overall population and [55.0% vs. 38.8% (p=0.002)] in the Eastern Cooperative Oncology Group performance status 0 group. There was no significant improvement in progression-free survival (PFS) and overall survival (OS) in either of these two groups of patients. CONCLUSION: In our real-world data analysis, patients treated with platin/paclitaxel/bevacizumab had better overall response rate (ORR), but not PFS or OS. Thus, both treatment regimens are similarly effective. Their selection should therefore be based on the potential side effects.
650    _2
$a senioři $7 D000368
650    _2
$a senioři nad 80 let $7 D000369
650    _2
$a protokoly protinádorové kombinované chemoterapie $x aplikace a dávkování $x škodlivé účinky $7 D000971
650    _2
$a bevacizumab $x aplikace a dávkování $x škodlivé účinky $7 D000068258
650    _2
$a nemalobuněčný karcinom plic $x farmakoterapie $x patologie $7 D002289
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a lidé $7 D006801
650    _2
$a inhibitory kontrolních bodů $x aplikace a dávkování $x škodlivé účinky $7 D000082082
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a metastázy nádorů $7 D009362
650    _2
$a paclitaxel $x aplikace a dávkování $x škodlivé účinky $7 D017239
650    _2
$a pemetrexed $x aplikace a dávkování $x škodlivé účinky $7 D000068437
650    _2
$a doba přežití bez progrese choroby $7 D000077982
655    _2
$a časopisecké články $7 D016428
700    1_
$a Opalka, Petr $u Department of Pneumology, Third Faculty of Medicine and Bulovka University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Krejci, Jana $u Department of Pneumology, Third Faculty of Medicine and Bulovka University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Zemanova, Milada $u Department of Oncology, First Faculty of Medicine in Prague, Charles University, Prague, Czech Republic
700    1_
$a Zemanova, Petra $u Department of Oncology, First Faculty of Medicine in Prague, Charles University, Prague, Czech Republic
700    1_
$a Kultan, Juraj $u Department of Respiratory Medicine, Faculty of Medicine and Olomouc University Hospital, Palacky University, Olomouc, Czech Republic
700    1_
$a Fischer, Ondrej $u Department of Respiratory Medicine, Faculty of Medicine and Olomouc University Hospital, Palacky University, Olomouc, Czech Republic
700    1_
$a Skrickova, Jana $u Department of Respiratory Diseases and TB, Faculty of Medicine and University Hospital Brno, Masaryk University Brno, Brno, Czech Republic
700    1_
$a Bratova, Monika $u Department of Respiratory Diseases and TB, Faculty of Medicine and University Hospital Brno, Masaryk University Brno, Brno, Czech Republic
700    1_
$a Cernovska, Marketa $u Department of Respiratory Medicine, First Faculty of Medicine and Thomayer University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Hrnciarik, Michal $u Department of Pneumology, Faculty of Medicine in Hradec Kralove, Charles University, Hradec Kralove, Czech Republic
700    1_
$a Coupkova, Helena $u Department of Comprehensive Oncology, Masaryk Institute of Oncology, Faculty of Medicine, Masaryk University, Brno, Czech Republic
700    1_
$a Hurdalkova, Karolina $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic
700    1_
$a Barinova, Magda $u Institute of Biostatistics and Analyses Ltd., Brno, Czech Republic
700    1_
$a Koubkova, Leona $u Department of Pneumology, Second Faculty of Medicine and Motol University Hospital, Charles University, Prague, Czech Republic
700    1_
$a Dolezal, Daniel $u Department of Pneumology, Masaryk Hospital Ústí nad Labem, Ústí nad Labem, Czech Republic
700    1_
$a Safanda, Martin $u Department of Clinical Oncology, Na Homolce Hospital, Prague, Czech Republic
700    1_
$a Pesek, Milos $u Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic
700    1_
$a Svaton, Martin $u Department of Pneumology and Phthisiology, Faculty of Medicine in Pilsen, Charles University, Pilsen, Czech Republic svatonm@fnplzen.cz
773    0_
$w MED00000478 $t Anticancer research $x 1791-7530 $g Roč. 41, č. 5 (2021), s. 2597-2603
856    41
$u https://pubmed.ncbi.nlm.nih.gov/33952489 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20210728 $b ABA008
991    __
$a 20210830100241 $b ABA008
999    __
$a ok $b bmc $g 1689678 $s 1139100
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 41 $c 5 $d 2597-2603 $e - $i 1791-7530 $m Anticancer research $n Anticancer Res $x MED00000478
LZP    __
$a Pubmed-20210728

Najít záznam

Citační ukazatele

Možnosti archivace